Clinical and economic impact of ferric carboxymaltose treatment for iron deficiency in patients stabilized following acute heart failure: a multinational study

References

• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–2200.
   PubMed Web of Science ®Google Scholar
• Your guide to heart failure. British Heart Foundation. 2018. Available from: www.bhf.org.uk/informationsupport/publications/heart-conditions/your-guide-to-heart-failure
   Google Scholar
• Kemp CD, Conte JV. The pathophysiology of heart failure. Cardiovasc Pathol. 2012;21(5):365–371.
   PubMed Web of Science ®Google Scholar
• Nieminen MS, Dickstein K, Fonseca C, et al. The patient perspective: quality of life in advanced heart failure with frequent hospitalisations. Int J Cardiol. 2015;191:256–264.
   PubMed Web of Science ®Google Scholar
• Peters-Klimm F, Kunz CU, Laux G, et al. Patient-and provider-related determinants of generic and specific health-related quality of life of patients with chronic systolic heart failure in primary care: a cross-sectional study. Health Qual life Outcomes. 2010;8(1):1–11.
   PubMedGoogle Scholar
• Pisa G, Eichmann F, Hupfer S. Assessing patient preferences in heart failure using conjoint methodology. Patient Prefer Adherence. 2015;9:1233.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Anker SD, AlHabib KF, et al. Heart failure: preventing disease and death worldwide. ESC Heart Fail. 2014;1(1):4–25.
   PubMedGoogle Scholar
• Lippi G, Sanchis-Gomar F. Global epidemiology and future trends of heart failure. AME Med J. 2020;5:15.
   Google Scholar
• Ezekowitz JA, McAlister FA, Armstrong PW. The interaction among sex, hemoglobin and outcomes in a specialty heart failure clinic. Can J Cardiol. 2005;21(2):165–171.
   PubMed Web of Science ®Google Scholar
• Beverborg NG, Klip IT, Meijers WC, et al. Definition of iron deficiency based on the gold standard of bone marrow iron staining in heart failure patients. Circ Heart Fail. 2018;11(2):e004519.
   PubMed Web of Science ®Google Scholar
• Jankowska EA, Malyszko J, Ardehali H, et al. Iron status in patients with chronic heart failure. Eur Heart J. 2012;34(11):827–834.
   PubMed Web of Science ®Google Scholar
• Jankowska EA, von Haehling S, Anker SD, et al. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J. 2013;34(11):816–829.
   PubMed Web of Science ®Google Scholar
• Shah R, Agarwal AK. Anemia associated with chronic heart failure: current concepts. Clin Interv Aging. 2013;8:111–122.
   PubMed Web of Science ®Google Scholar
• Enjuanes C, Klip IT, Bruguera J, et al. Iron deficiency and health-related quality of life in chronic heart failure: results from a multicenter European study. Int J Cardiol. 2014;174(2):268–275.
   PubMed Web of Science ®Google Scholar
• Klip IT, Comin-Colet J, Voors AA, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013;165(4):575.e3–582.e3.
   Web of Science ®Google Scholar
• McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726.
   PubMed Web of Science ®Google Scholar
• Cleland JG, Swedberg K, Follath F, et al. The EuroHeart Failure survey programme – a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003;24(5):442–463.
   PubMed Web of Science ®Google Scholar
• Maggioni AP, Dahlström U, Filippatos G, et al. EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2013;15(7):808–817.
   PubMed Web of Science ®Google Scholar
• Lesyuk W, Kriza C and Kolominsky-Rabas P. Cost-of-illness studies in heart failure: a systematic review 2004–2016. BMC Cardiovasc Disord. 2018;18(1):1–11.
   PubMedGoogle Scholar
• Ambrosy AP, Lewis GD, Malhotra R, et al. Identifying responders to oral iron supplementation in heart failure with a reduced ejection fraction: a post-hoc analysis of the IRONOUT-HF trial. J Cardiovasc Med. 2019;20(4):223–225.
   Google Scholar
• Drozd M, Jankowska EA, Banasiak W, et al. Iron therapy in patients with heart failure and iron deficiency: review of iron preparations for practitioners. Am J Cardiovasc Drugs. 2017;17(3):183–201.
   PubMed Web of Science ®Google Scholar
• Niehaus ED, Malhotra R, Cocca-Spofford D, et al. Repletion of iron stores with the use of oral iron supplementation in patients with systolic heart failure. J Card Fail. 2015;21(8):694–697.
   PubMed Web of Science ®Google Scholar
• Tolkien Z, Stecher L, Mander AP, et al. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS one. 2015;10(2):e0117383.
   PubMed Web of Science ®Google Scholar
• Kalra PR, Cleland JG, Petrie MC, et al.; IRONMAN Study Group. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet 2022;4:S0140-6736(22)02083-9.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Kirwan BA, Anker SD, et al. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure. Eur J Heart Fail. 2019;21(12):1651–1658.
   PubMed Web of Science ®Google Scholar
• Blumenstein I, Shanbhag S, Langguth P, et al. Newer formulations of intravenous iron: a review of their chemistry and key safety aspects–hypersensitivity, hypophosphatemia, and cardiovascular safety. Exp Opin Drug Saf. 2021;20(7):757–769.
   PubMed Web of Science ®Google Scholar
• Ehlken B, Nathell L, Gohlke A, et al. Evaluation of the reported rates of severe hypersensitivity reactions associated with ferric carboxymaltose and iron (III) isomaltoside 1000 in Europe based on data from EudraVigilance and VigiBase™ between 2014 and 2017. Drug Saf. 2019;42(3):463–471.
   PubMed Web of Science ®Google Scholar
• Glaspy JA, Lim-Watson MZ, Libre MA, et al. Hypophosphatemia associated with intravenous iron therapies for iron deficiency anemia: a systematic literature review. Therapeut Clin Risk Manag. 2020;16:245.
   PubMed Web of Science ®Google Scholar
• Kumar A, Brookes MJ. Iron therapy in inflammatory bowel disease. Nutrients. 2020;12(11):3478.
   PubMed Web of Science ®Google Scholar
• Mulder MB, van den Hoek HL, Birnie E, et al. Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside‐1000 (Monofer®) versus ferric carboxy‐maltose (Ferinject®). A single center, cohort study. Br J Clin Pharmacol. 2019;85(2):385–392.
   PubMed Web of Science ®Google Scholar
• Pollock RF, Biggar P. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia. Exp Rev Hematol. 2020;13(2):187–195.
   PubMed Web of Science ®Google Scholar
• Schaefer B, Tobiasch M, Viveiros A, et al. Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside—a systematic review and meta‐analysis. Br J Clin Pharmacol. 2021;87(5):2256–2273.
   PubMed Web of Science ®Google Scholar
• Gordon M, Sinopoulou V, Iheozor-Ejiofor Z, et al. Interventions for treating iron deficiency anaemia in inflammatory bowel disease. Cochrane Database Syst Rev. 2021;1(1):CD013529.
   Web of Science ®Google Scholar
• Vifor Pharma Limited. Ferinject (ferric carboxymaltose). 2021. Available from: https://www.medicines.org.uk/emc/product/5910/smpc.
   Google Scholar
• Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436–2448.
   PubMed Web of Science ®Google Scholar
• Jankowska EA, Kirwan BA, Kosiborod M, et al. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. Eur Heart J. 2021;42(31):3011–3020.
   PubMed Web of Science ®Google Scholar
• Khan MS, Usman MS, von Haehling S, et al. Ferric carboxymaltose for the treatment of iron-deficient heart failure patients: a systematic review and meta-analysis. ESC Heart Fail. 2020;7(6):3392–3400.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Kirwan B-A, Anker SD, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet. 2020;396(10266):1895–1904.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36(11):657–668.
   PubMed Web of Science ®Google Scholar
• van Veldhuisen DJ, Ponikowski P, van der Meer P, et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation. 2017;136(15):1374–1383.
   PubMed Web of Science ®Google Scholar
• McEwan P, Ponikowski P, Davis JA, et al. Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost-effectiveness analysis utilising AFFIRM-AHF. Eur J Heart Fail. 2021;23(10):1687–1697.
   PubMed Web of Science ®Google Scholar
• Rocha BML, Cunha GJL, Menezes Falcao LF. The burden of iron deficiency in heart failure: therapeutic approach. J Am Coll Cardiol. 2018;71(7):782–793.
   PubMed Web of Science ®Google Scholar
• Bagust A, Beale S. Survival analysis and extrapolation modeling of time-to-event clinical trial data for economic evaluation: an alternative approach. Med Decis Making. 2014;34(3):343–351.
   PubMed Web of Science ®Google Scholar
• Latimer NR. NICE decision support unit technical support documents, in survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data. London: National Institute for Health and Care Excellence (NICE); 2013.
   Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657.
   PubMed Web of Science ®Google Scholar
• Beattie JM, Khatib R, Phillips CJ, et al. Iron deficiency in 78 805 people admitted with heart failure across England: a retrospective cohort study. Open Heart. 2020;7(1): e001153.
   PubMed Web of Science ®Google Scholar
• Cleland JG, McDonagh T, Rigby AS, et al. The national heart failure audit for England and Wales 2008-2009. Heart. 2011;97(11):876–886.
   PubMed Web of Science ®Google Scholar
• Kutz A, Gut L, Ebrahimi F, et al. Association of the Swiss diagnosis-related group reimbursement system with length of stay, mortality, and readmission rates in hospitalized adult patients. JAMA Netw Open. 2019;2(2):e188332.
   PubMed Web of Science ®Google Scholar
• Beale A, Carballo D, Stirnemann J, et al. Iron deficiency in acute decompensated heart failure. J Clin Med. 2019;8(10):1569.
   PubMed Web of Science ®Google Scholar
• Annual report on hospitalization activity (SDO data 2018). Minister of Health Italy. 2019. Available from: www.salute.gov.it/portale/documentazione/p6_2_2_1.jsp?lingua=italiano&id=2898
   Google Scholar
• Orso F, Pratesi A, Herbst A, et al. Acute heart failure in the elderly: setting related differences in clinical features and management. J Geriatr Cardiol. 2021;18(6):407–415.
   PubMedGoogle Scholar
• Capewell S, Livingston B, MacIntyre K, et al. Trends in case-fatality in 117718 patients admitted with acute myocardial infarction in Scotland. Eur Heart J. 2000;21(22):1833–1840.
   PubMed Web of Science ®Google Scholar
• Hardoon SL, Whincup PH, Petersen I, et al. Trends in longer-term survival following an acute myocardial infarction and prescribing of evidenced-based medications in primary care in the UK from 1991: a longitudinal population-based study. J Epidemiol Commun Health. 2011;65(9):770–774.
   PubMed Web of Science ®Google Scholar
• Stewart A, Beaglehole R, Jackson R, et al. Trends in three-year survival following acute myocardial infarction, 1983–1992. Eur Heart J. 1999;20(11):803–807.
   PubMed Web of Science ®Google Scholar
• Bata IR, Gregor RD, Wolf HK, et al. Trends in five-year survival of patients discharged after acute myocardial infarction. Can J Cardiol. 2006;22(5):399–404.
   PubMed Web of Science ®Google Scholar
• Briffa T, Hickling S, Knuiman M, et al. Long term survival after evidence based treatment of acute myocardial infarction and revascularisation: follow-up of population based Perth MONICA cohort, 1984-2005. BMJ. 2009;338:b36.
   PubMedGoogle Scholar
• Botkin NF, Spencer FA, Goldberg RJ, et al. Changing trends in the long-term prognosis of patients with acute myocardial infarction: a population-based perspective. Am Heart J. 2006;151(1):199–205.
   PubMed Web of Science ®Google Scholar
• Shotan A, Gottlieb S, Goldbourt U, et al. Prognosis of patients with a recurrent acute myocardial infarction before and in the reperfusion era—a national study. Am Heart J. 2001;141(3):478–484.
   PubMed Web of Science ®Google Scholar
• Buch P, Rasmussen S, Gislason GH, et al. Temporal decline in the prognostic impact of a recurrent acute myocardial infarction 1985 to 2002. Heart. 2007;93(2):210–215.
   PubMed Web of Science ®Google Scholar
• UK NGC. Chronic heart failure in adults: diagnosis and management. National Institute for Health and Care Excellence (NICE). 2018. Available from: https://www.nice.org.uk/guidance/ng106
   Google Scholar
• Anand IS, Gupta P. Anemia and iron deficiency in heart failure: current concepts and emerging therapies. Circulation. 2018;138(1):80–98.
   PubMed Web of Science ®Google Scholar
• McCabe R, Schmit N, Christen P, et al. Adapting hospital capacity to meet changing demands during the COVID-19 pandemic. BMC Med. 2020;18(1):1–12.
   PubMed Web of Science ®Google Scholar
• Ressl S, Walter E, Bauer M. Budget-impact-analysis of iron treatment using intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Austria. Value Health. 2015;18(7):A384.
   Web of Science ®Google Scholar
• Walter E, Bauer M, Ressl S. Cost-effectiveness of ferric carboxymaltose in patients with iron deficiency and chronic heart failure in Austria. Value Health. 2015;18(7):A392.
   Web of Science ®Google Scholar
• Hofmarcher T, Cabrales Alin D, Linde C. Cost effectiveness of implementing ESC guidelines for treatment of iron deficiency in heart failure in the Nordic countries. Scand Cardiovasc J. 2018;52(6):348–355.
   PubMed Web of Science ®Google Scholar
• Rognoni C, Gerzeli S. Ferric carboxymaltose for patients with heart failure and iron deficiency in Italy: cost-effectiveness and budget impact. J Comp Eff Res. 2019;8(13):1099–1110.
   PubMed Web of Science ®Google Scholar
• Comín-Colet J, Rubio-Rodríguez D, Rubio-Terrés C, et al. A cost-effectiveness analysis of ferric carboxymaltose in patients with iron deficiency and chronic heart failure in Spain. Rev Esp Cardiol. 2015;68(10):846–851.
   PubMed Web of Science ®Google Scholar
• Delgado JF, Oliva J, González-Franco Á, et al. Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain. J Med Econ. 2020;23(12):1418–1424.
   PubMed Web of Science ®Google Scholar
• Bourguignon S, Faller M, Champs FO, et al. Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France. ESC Heart Fail. 2019;6(3):559–569.
   PubMed Web of Science ®Google Scholar
• Lorenzovici L, Székely A, Farkas-Ráduly S, et al. Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Romania. J Cardiovasc Emerg. 2019;5(4):131–139.
   Web of Science ®Google Scholar
• Rognoni C, Gerzeli S. Ferric carboxymaltose for patients with heart failure and iron deficiency in Italy: cost–effectiveness and budget impact. J Comp Eff Res. 2019;8(11):1099–1110.
   Google Scholar
• Theidel U, Väätäinen S, Martikainen J, et al. Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany. ESC Heart Fail. 2017;4(3):274–281.
   PubMed Web of Science ®Google Scholar
• National heart failure audit. 2019 summary report (2017/18 data). NICOR. 2019. Available from: https://www.nicor.org.uk/wp-content/uploads/2019/09/Heart-Failure-2019-Report-final.pdf
   Google Scholar